natgillin/translations-raw huggingface dataset:
1-sidet p-værdib
1-sided p-valueb
1-sidet p-værdic
1-sided p-valuec
1-trins koagulationsanalysen for faktor VIII aktivitet anbefales, da den er blevet anvendt til bestemmelse OBIZURs styrke og den gennemsnitlige bedringsrate (se pkt.
The one-stage assay is recommended because it has been used in determination of the potency and the mean recovery rate of OBIZUR (see sections 4.2 and 5.2).
1-års overlevelse,
1 year survival,
1-års overlevelsesrate (%)
1-year Overall survival rate (%)
1-års PFS-rate
1-year PFS Rate
1-års samlet overlevelse
1-year Overall survival rate
1.
EXP
1. behandling
1st Course
1. behandling
1st treatment
1. behandlingsforløb: 12 mg/dag på 5 fortløbende dage (samlet dosis 60 mg)
Initial treatment course: 12 mg/day on 5 consecutive days (60 mg total dose)
1. dag – fuld dosis (1000 mg)
Day 1 - full dose (1,000 mg)
1. dag – fuld dosis (1000 mg)
Day 1 - full dose (1,000 mg).
1. dag – fuld dosis (1000 mg)
Day 1 – full dose (1,000 mg).
1. dag – første del af din 1. dosis (100 mg)
Day 1 – part of your first dose (100 mg)
1. dosis 2. dosis
1st Dose 2nd Dose
1. dosis 2. dosis 1. dosis 2. dosis
1st Dose 2nd Dose 1st Dose 2nd Dose
1. dosis n = 59
Post dose 1
1. dosis n = 92
Post dose 1
1. forekomst af enhver grad 2 eller 3 bivirkning
1st occurrence of any grade 2 or 3 AE
1. forekomst af enhver grad 4 bivirkning
1st occurrence of any grade 4 AE
1. forekomst: 40 mg
1st occurrence: 40 mg
1. förfylld pen
1 pre-filled pen
1. indsprøjtning:
1st administration:
1. injektion: 10 mg/kg,
1st injection: 10 mg/kg,
1. kvartal 2017
1Q 2017
1. leveår Rotarix n = 2.572 Placebo n = 1.302
Rotarix N=2572 Placebo N=1302
1. linje-B-CLL-patienter
First line B-CLL patients
1. reduktion af dosisniveau
1st dose level reduction
1. uge (dag 1-7):
Week1 (day 1-7):
1. uge (dag 1-7):-
Week 1 (day 1-7):
1. år
1st year
1., 2. eller booster-), var sammenlignelig og er anført efter frekvens som følger:
1st, 2nd or booster) were similar and are listed according to the following frequency:
1.,5 (1,24, 2,20), P=0,0007
1.65 (1.24, 2.20), P=0.0007
1.-linjebehandling af ikke-planocellulær NSCLC med EGFR-aktiverende mutationer i kombination med erlotinib
First-line treatment of non-squamous NSCLC with EGFR activating mutations in combination with erlotinib
1.0
PARAMOUNT
1.0 mg 4 gange daglig
1.0 mg QD
1.0 mg/kg/uge
1.0 mg/kg/wk
1.0 OTFC (normaliseret til 400 mcg)
OTFC (normalized to 400 mcg)
1.00 (0,92-1,10)
GIVEN WITH
1.000 børn (78 %) mellem juli 2004 (før Prevenar blev introduceret) og juni 2013 (efter Prevenar 13 var introduceret).
2.1 cases per 1000 children (78%) between July 2004 (prior to the introduction of Prevenar) and June 2013 (post Prevenar 13 introduction).
1.000 doser
1,000 doses
1.000 doser
10,000 doses
1.000 doser
1000 doses
1.000 doser
5,000 doses
1.000 doser (3-100 kugler) 5.000 doser (3-100 kugler) 10.000 doser (3-400 kugler)
1,000 doses (3-100 spheres) 5,000 doses (3-100 spheres) 10,000 doses(3-400 spheres)
1.000 HRT-
1,000 HRT users
1.000 IE
1000 IU
1.000 IE/0,5 ml
1,000 IU/0.5 ml
1.000 kvindeår gennem den 3-årige studieperiode 2,86 i bazedoxifengruppen (20 mg) og 1,76 i placebogruppen og gennem den 5-årige studieperiode var den 2,34 i bazedoxifengruppen med 20 mg og 1,56 i placebogruppen.
1.76 in the placebo group and through the 5-year study period was 2.34 in the bazedoxifene 20 mg group and 1.56 in the placebo group.
1.000 mg 2 gange daglig plus ritonavir 100 mg 2 gange daglig* (måltid med højt fedtindhold)
ritonavir 100 mg bid* (high fat meal)
1.000 mg q8h blev givet sammen
Fosamprenavir/Saquinavir/
1.000 mg q8h blev givet sammen
indinavir 1,000 mg q8h was given
1.000 mg q8h blev givet sammen med
indinavir 1,000 mg q8h was given
1.000 mg saquinavir to gange daglig med 100 mg ritonavir to gange daglig hos ART-erfarne patienter.
Saquinavir 1000 mg twice daily with ritonavir 100 mg twice daily in ART experienced patients.
1.000 mg saquinavir to gange daglig medfører en systemisk saquinavireksponering i løbet af 24 timer, som svarer til eller er større end den, der opnås med 1.200 mg saquinavir tre gange daglig uden ritonavir.
Ritonavir100 mg twice daily with saquinavir 1000 mg twice daily provides saquinavir systemic exposure over 24 hours similar to or greater than those achieved with saquinavir 1200 mg three times daily without ritonavir.
1.000 mg to gange dagligt fik plasmakoncentrationen af simvastatinlacton og simvastatinsyre til at stige med cirka en faktor 2.
1000 mg twice daily increased plasma concentrations of simvastatin lactone, simvastatin acid by about 2 fold.
1.000 mg to gange dagligt fik plasmakoncentrationen af simvastatinlacton og simvastatinsyre til at stige med faktor 2.
1000 mg twice daily increased plasma concentrations of simvastatin lactone, simvastatin acidby about 2-fold.
1.000 mg x 2
1,000 mg twice daily
1.000 mg/100 mg 2 gange daglig (maraviroc 100 mg 2 gange daglig)
(maraviroc 100 mg BID)
1.000 mg/da g
1,000 mg/day
1.000 mg/dag
1,000 mg/day
1.000 mg/kg darunavir (enkeltdosis) i en alder på 26 dage eller en dosis på 500 mg/kg (gentagen dosis) i alderen fra 23 til 50 dage, og eksponeringen og toksicitetsprofilen var sammenlignelige med dem, der blev observeret hos voksne rotter.
500 mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and toxicity profile were comparable to those observed in adult rats.
1.000 mg/m
1000 mg/m2
1.000 mg/m2
1250 mg/m2
1.000 mg/m2 oral 2
1000 mg/m2 oral
1.000 mg/m2 oral 2 gange daglig
1000 mg/m2 oral twice daily
1.000 mg/m2 oral to gange daglig
1000 mg/m2 oral bid
1.000 mg/m2 oralt 2 gange daglig
1000 mg/m2 oral twice daily
1.000 mg/m² 5-fluoruracil (F) dagligt i 5 dage.
1000 mg/m² per day for 5 days.
1.000 mg: 10, 20, 30, 50, 60, 100 x 1, 100 filmovertrukne tabletter og multipakning indeholdende 200 (2 pakninger med 100) filmovertrukne tabletter
1000 mg: 10, 20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
1.000 ml
1,000 mL
1.000 ml (5 x 200 ml)
1,000 ml (5 x 200 ml)
1.000 ng/ml, hvilket ca. svarer til en stigning på 2 til 7 millisekunder i plasmakoncentrationsområdet for ranolazin 500 til 1.000 mg administreret to gange dagligt.
2.4 msec per 1000 ng/ml, which is approximately equal to a 2- to 7-msec increase over the plasma concentration range for ranolazine 500 to 1000 mg twice daily.
1.000 patienter), men alvorlig bivirkning, som kan være livstruende.
1,000 patients) but serious side effect that can be fatal.
1.000 patientår i relation til eksponering.
1,000 patient-years, respectively of exposure.
1.000 patientår.
1,000 patient years, respectively.
1.000 – 10.000 kopier/ml
1000 – 10,000 copies/ml
1.000, 2.000 eller 3.000 mg levetiracetam, og 12,6 % for patienter, som fik placebo.
31.6 % and 41.3 % for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6 % for patients on placebo.
1.000, 2.000 eller 3.000 mg levetiracetam, og 12,6 % for patienter, som fik placebo.
31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo.
1.000-1.200 mg dagligt (1.000 mg til patienter, der vejer < 75 kg, og 1.200 mg til patienter, der vejer
1,000-1,200 mg daily (1,000 mg for patients weighing <75 kg and 1,200 mg for patients weighing
1.000.000 celler/cm²
1,000,000 cells/cm²
1.000/100 mg 2 gange
1000/100 mg bid)
1.000/100 mg 2 gange
1200 mg tid)
1.000/100 mg to gange
1,000/100 mg twice daily
1.060 patienter blev randomiseret til at få enten TAXOTERE 75 mg/m2 administreret 1 time efter doxorubicin 50 mg/m2 og cyclophosphamid 500 mg/m2 (539 patienter i TAC-armen) eller doxorubicin 50 mg/m2 efterfulgt af fluoruracil 500 mg/m2 og cyclophosphamid 500 mg/m2 (521 patienter i FAC-armen) som adjuverende behandling.
1060 patients were randomized to receive either TAXOTERE 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in
1.093 patienter med stadie IV (American Joint Committee on Cancer, 7. udgave) planocellulær NSCLC, herunder patienter med en ECOG PS 2, der ikke tidligere havde fået anticancer-behandling for metastatisk sygdom.
1,093 patients with stage IV (American Joint Committee on Cancer Version 7) squamous NSCLC, including patients with ECOG PS2, who had received no prior anticancer therapy for metastatic disease.
1.1 % for hhv. clopidogrel+ASA- og placebo+ASA-gruppen.) Dette var ensartet blandt undergrupperne af patienter, defineret ved baseline karakterisktika og typen af fibrinolytika eller heparinbehandling.
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
1.1%) og ny- diagnosticeret perifer vaskulær sygdom (PVD) eller indlæggelse for PVD-operation (1,4% vs.
1.1%), and new diagnosis of peripheral vascular disease (PVD) or admission for a PVD procedure (1.4% vs.
1.100 kBq/ml
1100 kBq/mL
1.12 ml 2 pipetter Ikke relevant
2 tablets Not applicable
1.12 ml 4 pipetter Ikke relevant
4 tablets Not applicable
1.200 IE (87 g)/hætteglas
1200 IU (87 g)/vial
1.200 mg 3 gange
1200 mg tid)
1.200 mg enkeltdosis)
1600/100 mg qd)
1.200 mg hver 14. dag ± 2 dage i den resterende del af studiet.
1,200 mg 7  2 days later, then 1,200 mg every 14 ± 2 days for the study duration.
1.200 mg)d
1,200 mg)d
1.200 mg)d
p valueb
1.200 mg/dag) d + interferon alfa-2b (3 MIE TIW)
1,200 mg/day) d + interferon alfa-2b (3 MIU TIW)
1.200 mg/m2
1,200 mg/m2
1.200 µg/kg 800 µg/kg
800 μg/kg
1.206 pædiatriske patienter i alderen 3 måneder til 17 år blev inkluderet i ARROW-studiet (COL105677) og blev doseret i henhold til vægtgruppe-anbefalingerne i WHO’s behandlingsvejledning (Antiretroviral therapy of HIV infection in infants and children, 2006).
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
1.206 pædiatriske patienter i alderen måneder til 17 år blev inkluderet i ARROW-studiet (COL105677) og blev doseret i henhold til vægtgruppe-anbefalingerne i WHO’s behandlingsvejledning (Antiretroviral therapy of HIV infection in infants and children, 2006).
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight-band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006).
1.216 antiretroviralterapi-naive patienter med plasma hiv-1-RNA ved baseline > 5.000 kopier/ml blev i 48 uger allokeret til Viramune 400 mg én gang daglig, Viramune 200 mg to gange daglig, efavirenz 600 mg én gang daglig eller Viramune (400 mg) og efavirenz (800 mg) én gang daglig plus stavudin og lamivudin.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
1.218 patienter med inoperabel ikke-småcellet lungekræft stadium IIIB eller IV med KPS på 70 % eller mere og som ikke tidligere havde fået kemoterapi mod denne tilstand, blev i et fase III-studie randomiseret til enten docetaxel (T) 75 mg/m2 administreret som 1-times infusion umiddelbart efterfulgt af cisplatin (Cis) 75 mg/m2 administreret i løbet af 30-60 minutter hver 3. uge (TCis), docetaxel 75 mg/m2 som en 1-times infusion i kombination med carboplatin (AUC 6 mg/ml pr. min) administreret i løbet af 30-60 minutter hver 3. uge eller vinorelbin (V) 25 mg/ m2 administreret i løbet af 6 til 10 minutter på dag 1, 8, 15, 22 efterfulgt af cisplatin 100 mg/m2 administreret på dag 1 af cyklusser gentaget hver 4. uge (VCis).
In a phase III study, 1,218 patients with unresectable stage IIIB or IV NSCLC, with KPS of 70% or greater, and who did not receive previous chemotherapy for this condition, were randomised to either Docetaxel (T) 75 mg/m2 as a 1 hour infusion immediately followed by cisplatin (Cis) 75 mg/m2 over 30-60 minutes every 3 weeks (TCis), Docetaxel 75 mg/m2 as a 1 hour infusion in combination with carboplatin (AUC 6 mg/ml. min) over 30-60 minutes every 3 weeks, or vinorelbine (V) 25 mg/m2 administered over 6-10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m2 administered on day 1 of cycles repeated every 4 weeks (VCis).
1.218 patienter med inoperabel ikke-småcellet lungekræft stadium IIIB eller IV med KPS på 70 % eller mere, og som ikke tidligere havde fået kemoterapi mod denne tilstand, blev i et fase III-studie randomiseret til enten docetaxel (T) 75 mg/m2 administreret som 1-times infusion umiddelbart efterfulgt af cisplatin (Cis) 75 mg/m2 administreret i løbet af 30-60 minutter hver 3. uge (TCis), docetaxel 75 mg/m2 som en 1-times infusion i kombination med carboplatin (AUC 6 mg/ml pr. min) administreret i løbet af 30-60 minutter hver 3. uge eller vinorelbin (V) 25 mg/ m2 administreret i løbet af 6 til 10 minutter på dag 1, 8, 15, 22 efterfulgt af cisplatin 100 mg/m2 administreret på dag 1 af cyklusser gentaget hver 4. uge (VCis).
In a phase III study, 1218 patients with unresectable stage IIIB or IV NSCLC, with KPS of 70% or greater, and who did not receive previous chemotherapy for this condition, were randomised to either docetaxel (T) 75 mg/m2 as a 1 hour infusion immediately followed by cisplatin (Cis) 75 mg/m2 over 30-60 minutes every 3 weeks (TCis), docetaxel 75 mg/m2 as a 1 hour infusion in combination with carboplatin (AUC 6 mg/ml. min) over 30-60 minutes every 3 weeks, or vinorelbine (V) 25 mg/m2 administered over 6-10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m2 administered on day 1 of cycles repeated every 4 weeks (VCis).
1.239 i qHPV-vaccinationsgruppen) mindst én graviditet.
1,239 in the qHPV vaccine group) reported at least one pregnancy.
1.25 - 2.5 kg
½ tablet
1.250 mg/m
1250 mg/m2
1.250 mg/m2
1250 mg/m2
1.269 patienter med let nedsat nyrefunktion og 161 patienter med moderat nedsat nyrefunktion, der alle blev behandlet med alogliptin/pioglitazon.
The studies included 1,269 patients with mild renal impairment and 161 patients with moderate renal impairment treated with alogliptin/pioglitazone.
1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclofosfamid (bivirkninger til klinisk vigtig behandling er præsenteret).
1,276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclofosfamid (bivirkninger til klinisk vigtig behandling er præsenteret).
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclophosphamid (bivirkninger til klinisk vigtig behandling er præsenteret).
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclophosphamid (klinisk relevante behandlingsrelaterede bivirkninger er nævnt).
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclophosphamid (klinisk vigtige behandlingsrelaterede bivirkninger er nævnt).
1,276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805),, som fik docetaxel i kombination med doxorubicin og cyclofosfamid (bivirkninger til klinisk vigtig behandling er præsenteret).
1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.276 patienter (744 og 532 i henholdsvis TAX 316 og GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclophosphamid (klinisk relevante behandlingsrelaterede bivirkninger er medtaget).
1,276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
1.282 patienter i studie 1 (IBS-3001) og 1.146 patienter i studie 2 (IBS-3002), som fik Truberzi 75 mg, Truberzi 100 mg eller placebo to gange dagligt.
1,282 patients in Study 1 (IBS-3001) and 1,146 patients in Study 2 (IBS-3002) were enrolled and received treatment with Truberzi 75 mg, Truberzi 100 mg or placebo twice daily.
1.312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 af doceraxel som enkeltstof.
1312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively.
1.312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 af doceraxel som enkeltstof.
1312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1.312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 af docetaxel som enkeltstof.
1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1.312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 docetaxel som enkeltstof.
1,312 and 121 patients who received 100 mg/m2 and 75 mg/ m2 of docetaxel as a single agent respectively.
1.312 og 121 patienter, som fik henholdsvis 100 mg/m2 og 75 mg/m2 docetaxel som enkeltstof.
1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively.
1.33 ml/10 kg kropsvægt) på førstedagen.
1.33 ml/10 kg bodyweight) on the first day.
1.367 nukleosidnaive HBeAg-positive og HBeAg-negative patienter med kronisk hepatitis B. Størstedelen af de inkluderede patienter var asiater.
The majority of the population enrolled was Asian.
1.400 mikrogram og 1.600 mikrogram filmovertrukne tabletter leveres i blisterpakninger med 60 tabletter.
1,400 microgram, and 1,600 microgram film-coated tablets are supplied in blister packs of 60 tablets.
1.407 patienter, der blev behandlet i op til 9 dage i forbindelse med abdominal kirurgi
1,407 patients undergoing abdominal surgery treated up to 9 days
1.500 IE
1500 IU
1.500 mg to gange dagligt
1500 mg twice daily
1.500 mg/m2/døgn blev givet intravenøst over 2 timer på dag 1, 3 og 5 i en cyklus på 21 dage.
Nelarabine at a dose of 1500 mg/m2/day was administered intravenously over two hours on days 1, 3 and 5 of a 21 day cycle.
1.55 (1,05; 2,06)c
1.55 (1.05, 2.06) c
1.6 g pulver til oral suspension
1.6 g powder
1.600 mg/m2
1,600 mg/m2
1.600-2.400 IE
1,600 – 2,400 IU
1.662.500 IU
1,662,500
1.7
SA.U
1.750 IE antithrombin alfa
1750 IU of antithrombin alfa
1.8.2 i markedsføringstilladelsen, og enhver efterfølgende godkendt opdatering af RMP.
An updated RMP should be submitted
1.8.2 i markedsføringstilladelsen, og enhver efterfølgende godkendt opdatering af RMP.
An updated RMP should be submitted:
1.8.2. i markedsføringstilladelsen, og enhver efterfølgende opdatering af RMP, som er godkendt af Udvalget for Lægemidler til Mennesker (CHMP).
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP).
1.800 mg/dag eller
1,800 mg/day or
1.900 MBq/ml
1900 MBq/ml
1.91‡‡
Exenatide+
1.niveau reduktion (mikrogram)
1 level reduction (mcg)
1.Ved data-afslutning (20. april 2012)
1 At data cut off (20 April 2012)
1/1
1 vial
1/1
Actavis
1/28 (4 %) i kontrolarmen.
1/28 (4%) in the control group.
10 % af totaldosis 40 minutter efter dosisadministration (jf.
10% of the total dose 40 minutes after dose administration (cf.
10 % imidacloprid og 1,0 % moxidectin
10% imidacloprid
10 % imidacloprid og 2,5%
10% imidacloprid
10 % imidacloprid og 2,5% moxidectin
10% imidacloprid
10 % imidacloprid og 2,5% moxidectin
Route of administration
10 % tærskelværdi
10% threshold
10 %, p < 0,0001.
10%, p < 0.0001.
10 (1 x 10) hætteglas (multipakning)
10 (1 x 10) vial (multipack)
10 (10 x 1) flasker (Multipakning)
10 (10 x 1) (multipack)
10 (10 x 1) fyldte sprøjter (multipakke)
10 (10x1) pre-filled syringe (multipack)
10 (10 x 1) poser (Multipakning)
10 (10 x 1) bag (multipack)
10 (10x1) flasker (multipakning)
10 (10x1) bottles (multipack)
10 (10x1) poser (multipakning)
10 (10x1) bags (multipack)
10 (2 pakninger a 5) fyldte penne (multipakning)
10 (2 packs of 5) pre- filled pens (multipack)
10 (2 x 5) cylinderampuller (flerstykspakning)
10 (2 x 5) cartridges (multipack)
10 (2 x 5) fyldte penne (flerstykspakning)
10 (2 x 5) pre- filled pens (multipack)
10 (2 x 5) fyldte penne (flerstykspakning)
10 (2 x 5) pre-filled pens (multipack)
10 (2 x 5) fyldte penne (flerstykspakning)
10 (2x5) pre-filled pens (multipack)
10 (2 x 5) fyldte penne (multipakning)
10 (2 x 5 ) pre- filled pens (multipack)
10 (2x5) fyldte penne (flerstykspakning)
10 (2x5) pre- filled pens (multipack)
10 (5 x 2) AutoClicks fyldte penne + 10 (5 x 2) alkoholservietter (multipakning)
10 (5 x 2) Autoclicks pre-filled pen + 10 (5x2) alcohol wipes (multipack)
10 - For at kunne trække opløsningen tilbage i injektionssprøjten, vender du det samlede injektionssprøjte-hætteglas med kanylen pegende opad.
10 - In order to redraw the solution back into the syringe turn the syringe-vial-assembly, needle pointing upwards.
10 1 fyldt sprøjte
10 pre-filled syringes
10 5.7 til 10
10 5.7 to
10 A-6250 Kundl Østrig.
10 A-6250 Kundl Austria
10 aluminium-
10 aluminium
10 ampuller +
10 vials + 10 vials
10 ampuller: solvens
10 ampoules: solvent
10 August 2006.
10 August 2006
10 av. de La Ballastière 33500 Libourne FRANKRIG
10 av. de La Ballastière 33500 Libourne FRANCE
10 bløde tuber
10 squeezable tubes
10 breve
10 sachets
10 bæger
10 cups
10 cylinder- ampuller
10 cartridges
10 cylinderampuller
10 cartridges
10 cylindermapuller
10 cartridges
10 dage efter den første dosis (hvilket er tiden til maksimal koncentration (Tmax) af desoxycorton).
10 days after the first dose (which is the time to maximum concentration (Tmax) of desoxycortone).
10 dage efter den første dosis (som er tiden til maksimal koncentration (Tmax) af desoxycorton).
10 days after the first dose (which is the time to maximum concentration (Tmax) of desoxycortone).
10 delpakninger (1 færdigfyldt sprøjte)
10 intermediate packs (1 pre-filled syringe)
10 depottabletter
10 prolonged-release tablets
10 depottabletter
10 tablets
10 Der er blevet rapporteret dødelige tilfælde hos patienter med fremskreden sygdom, alvorlige infektioner, alvorlig neutropeni og andre alvorlige, samtidige tilstande.
Fatal cases have been reported in patients with advanced disease, severe infections, severe neutropenia and other serious concomitant conditions.
10 dispergible tabletter
10 dispersible tablets
10 dispergible tabletter 30 dispergible tabletter 100 dispergible tabletter
10 dispersible tablets 30 dispersible tablets 100 dispersible tablets
10 doser (10 ml)
10 doses (10 ml)
10 doser (2,5 ml)
10 doses (2.5 ml)
10 doser (20 ml).
10 doses (20 ml)
10 doser (20 ml).
10 doses (20 ml).
10 doser (5 ml)
10 doses (5 ml)
10 doser (5 ml).
10 doses (5 ml).
10 doser = 20 ml hætteglas
10 doses = 20 ml vial.
10 EFT L 143 af 26.06.95
10 OJ No L 143 of 26.06.95